CVS Health shares that hit an all-time high price three months ago tumbled Friday after the drug store chain and pharmacy benefits manger surprised Wall Street with a 2016 profit forecast that fell well below expectations.
The Woonsocket, Rhode Island, company also detailed third-quarter earnings that missed analyst forecasts.
CVS executives preached patience Friday after forecasting adjusted 2016 earnings of between $5.68 and $5.88 per share.
Analysts expected, on average, earnings of $5.99 per share, according to FactSet.
CVS leaders said on a conference call with analysts that their company is feeling immediate pressure from payers like health insurers and the government programs Medicare and Medicaid over the reimbursement it receives for filling prescriptions, while the business gains it is reaping will take time to develop.
CVS Health operates the nation’s second-largest drugstore chain and one of the biggest pharmacy benefits management businesses.
The company said it has gained some large clients for its pharmacy benefits management, or PBM, business, but it takes time to implement programs like Maintenance Choice that will pull additional profits from that new business. Maintenance Choice allows patients to fill 90-day prescriptions delivered through the mail or pick them up at CVS stores for the same price.
“We feel really good about our positioning in the marketplace and our strategy,” CEO Larry Merlo said.
In the third quarter, CVS Health earned $1.24 billion, not counting $10 million in discontinued operations. That compares to $948 million in last year’s quarter, when the company absorbed a $521-million loss on the early retirement of some debt.
Earnings, adjusted for one-time gains and costs, came to $1.28 per share.
That fell two cents short of the average analyst expectation, according to Zacks Investment Research.
But the company’s revenue grew 10 per cent to $38.64 billion, which topped the average analyst forecast for $37.76 billion.
CVS Health runs 7,911 drugstores in 44 states, the District of Columbia and Brazil. Its earnings announcement came a couple days after larger competitor Walgreens Boots Alliance Inc. announced plans to get even bigger in the United States by adding Rite Aid Corp.’s 4,600 stores to its portfolio of more than 8,000.
CVS Health draws most of its revenue from its PBM business, which runs prescription drug plans for customers like insurers and employers. That diversity is expected to help counter any additional competitive crunch its retail side may feel from the Walgreens deal. Plus CVS has been doing some shopping of its own. It is buying the pharmacy and clinic businesses of retail giant Target Corp.
And in August, the company closed a more than $10-billion deal to buy the pharmaceutical distributor Omnicare. That acquisition that will give it national reach in dispensing prescription drugs to assisted living and skilled nursing homes, long-term care facilities, hospitals and other care providers.
Omnicare started contributing to the CVS income statement in the third-quarter, but the company also booked a higher interest expense and income taxes because of the deal.
CVS Health also on Friday tightened its forecast for current year to $5.14 to $5.18 per share after narrowing it in August to $5.11 to $5.18 per share.
FactSet says analysts expect $5.16 per share.
Shares of CVS Health fell nearly 4 per cent, or $4.02, to $99.78 in midday trading Friday while broader indexes were nearly flat. CVS Health shares had climbed nearly 8 per cent since the beginning of the year, as of Thursday’s close, while the Standard & Poor’s 500 index had advanced 1.5 per cent. The stock hit an all-time high of $113.65 in late July.